May 5, 2023 07:07 AM EDT

Maria Fardis ends a two-year CEO hiatus; More leadership turnover on the menu at Galapagos

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ Following her resignation from Iovance, Maria Fardis pivoted to Frazier Life Sciences as a venture partner. But she’s back in the saddle at a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Maria Fardis ends a two-year CEO hiatus; More leadership turnover on the menu at Galapagos

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Maria Fardis ends a two-year CEO hia­tus; More lead­er­ship turnover on the menu at Gala­pa­gos

Copy Chief

Editor

Sign up to read this article for free.

Maria Fardis ends a two-year CEO hiatus; More leadership turnover on the menu at Galapagos